On this page of StockholderLetter.com we present the latest annual shareholder letter from Clene Inc. — ticker symbol CLNN. Reading current and past CLNN letters to shareholders can bring important insights into the investment thesis.
REVOLUTIONIZING TREATMENT TO RESTORE AND PROTECT NEURONAL HEALTH FOR THOSE LIVING WITH NEURODEGENERATIVE DISEASES 2024 ANNUAL REPORT
2024: New Long-Term Evidence with CNM-Au8 Treatment in ALS Brings Hope 1 Relationship between long-term reduction of NfL biomarker levels and survival improvement in amyotrophic lateral sclerosis (ALS) 1. Signi cant clinical improvements in survival and functional status (slowed ALSFRS-R decline) in neuro lament light (NfL) responders compared to NfL non-responders on CNM-Au8 30 mg treatment New long-term data backed by evidence from three independent sources: HEALEY ALS Platform Trial, RESCUE-ALS and two EAPs 2. Independent of NfL responder status, signi cant survival bene ts in CNM-Au8 30 mg treated participants were observed in the long-term extension compared to matched natural history controls 2 Long-term survival bene t in patients with late-stage ALS from Early Access Protocols (EAPs) 1. Signi cant survival bene t in ALS EAP programs vs natural history controls with CNM-Au8 30 mg treatment
What is Neuro lament Light Chain (NfL) and Why is it Important? NfL is a Key Biomarker of Disease Progression and Mortality Risk in ALS Patients Neuro lament Light Chain Protein Cytoskeletal proteins that provide structure and support for the cell and are highly speci c for neurons Axonal damage: high NfL levels are associated with axonal damage Neuro lament Light High NfL in ALS: predicts greater risk of disease progression
Goal: Demonstrate that the Surrogate Endpoint, NfL Biomarker, Predicts Clinical Survival Bene t with CNM-Au8 30 mg Treatment in ALS Long-Term Survival Bene t - 91% Risk Reduction of Death in Participants with any NfL Decline at 24-Weeks 91% Risk Reduction
2024: New Long-Term Evidence with CNM-Au8 Treatment in Multiple Sclerosis (MS) Brings Hope 3 Long-term cognitive and vision improvement in MS 1. Improved vision and cognitive function supporting remyelination and reparative effects in stable MS patients on top of standard of care with CNM-Au8 30 mg treatment 4 Safety 1. >800 Years of Participant Exposure without Identi ed Safety Signals in ALS, MS and Parkinson's disease CNM-Au8 A gold nanocrystal suspension, the rst cellular energetic catalyst
 • shareholder letter icon 4/8/2025 Letter Continued (Full PDF)
 • stockholder letter icon 3/29/2023 CLNN Stockholder Letter
 • stockholder letter icon 4/16/2024 CLNN Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon CLNN Benford's Law Stock Score = 91


CLNN Shareholder/Stockholder Letter Transcript:

REVOLUTIONIZING TREATMENT TO
RESTORE AND PROTECT NEURONAL
HEALTH FOR THOSE LIVING WITH
NEURODEGENERATIVE DISEASES
2024
ANNUAL
REPORT

2024: New Long-Term Evidence
with CNM-Au8   Treatment in ALS Brings Hope
1
Relationship between long-term reduction of
NfL biomarker levels and survival improvement
in amyotrophic lateral sclerosis (ALS)
1. Signi   cant clinical improvements in survival and
functional status (slowed ALSFRS-R decline) in
neuro   lament light (NfL) responders compared to
NfL non-responders on CNM-Au8 30 mg treatment
New long-term
data backed by
evidence from
three independent
sources: HEALEY
ALS Platform Trial,
RESCUE-ALS and
two EAPs
2. Independent of NfL responder status, signi   cant
survival bene   ts in CNM-Au8 30 mg treated
participants were observed in the long-term
extension compared to matched natural history
controls
2
Long-term survival bene   t in patients
with late-stage ALS from Early Access
Protocols (EAPs)
1. Signi   cant survival bene   t in ALS EAP programs
vs natural history controls with CNM-Au8 30 mg
treatment

What is Neuro   lament Light Chain (NfL)
and Why is it Important?
NfL is a Key Biomarker of Disease Progression and Mortality
Risk in ALS Patients
Neuro   lament Light Chain Protein
Cytoskeletal proteins that
provide structure and
support for the cell and are
highly speci   c for neurons
Axonal damage: high NfL
levels are associated with
axonal damage
Neuro   lament
Light
High NfL in ALS: predicts
greater risk of disease
progression

Goal: Demonstrate that the Surrogate Endpoint,
NfL Biomarker, Predicts Clinical Survival Bene   t with
CNM-Au8 30 mg Treatment in ALS
Long-Term Survival Bene   t - 91% Risk Reduction
of Death in Participants with any NfL Decline
at 24-Weeks
91%
Risk
Reduction

2024: New Long-Term Evidence with CNM-Au8
Treatment in Multiple Sclerosis (MS) Brings Hope
3
Long-term cognitive and
vision improvement in MS
1. Improved vision and cognitive function supporting
remyelination and reparative effects in stable MS patients
on top of standard of care with CNM-Au8 30 mg treatment
4
Safety
1. >800 Years of Participant Exposure without
Identi   ed Safety Signals in ALS, MS and
Parkinson's disease
CNM-Au8  
A gold
nanocrystal
suspension,
the    rst
cellular
energetic
catalyst



shareholder letter icon 4/8/2025 Letter Continued (Full PDF)
 

CLNN Stockholder/Shareholder Letter (Clene Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.